CymaBay Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the treatment of liver and chronic diseases. Its lead product candidate, seladelpar, a selective agonist of peroxisome proliferator activated receptor delta is currently in phase III trials for the treatment of primary biliary cholangitis. Additionally, the company is developing MBX-2982, which is currently in Phase 2a clinical study for hypoglycemia in type 1 diabetics.